October 24, 2011 10:30 AM Eastern Daylight Time
Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
PARIS--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the appointment of David
Meeker as Chief Executive Officer of Genzyme,
a Sanofi company, effective November 1, 2011. He will report to
Christopher A. Viehbacher, Chief Executive Officer of Sanofi, and will
join the Group Management Committee. Christopher A. Viehbacher will
retain the position of Chairman, Genzyme.
“After working closely with David over the past six months, I am
confident that he is the best person to lead Genzyme”
“After working closely with David over the past six months, I am
confident that he is the best person to lead Genzyme,” said
Christopher A. Viehbacher, Chief Executive Officer of Sanofi.
“David’s commitment to employees, physicians and patients has been a key
success factor in the successful integration of Genzyme as part of the
Sanofi Group. His combination of medical and business experience
will be essential to move Genzyme’s broad portfolio of products forward
and deliver much-needed therapies to patients.”
Under David Meeker’s leadership, Genzyme will incorporate the Rare
Disease business and the Multiple Sclerosis franchise. Previous Genzyme
divisions - Renal, Biosurgery and Oncology - have been integrated within
the existing Sanofi portfolio giving them greater global scale and
capabilities.
David joined Genzyme in 1994 as Medical Director to work on the Cystic
Fibrosis Gene Therapy program. Over the years he has held key positions
of increasing responsibility as he led the development of treatments in
the current rare disease portfolio. As President of the Global Rare
Disease Business, he oversaw the global launches of Aldurazyme®,
Fabrazyme® and Myozyme®. In 2009, he was promoted
to Chief Operating Officer of Genzyme and has played an important role
in the integration since April of this year. David received his M.D.
from the University of Vermont Medical School, and completed the
Advanced Management Program at Harvard Business School in 2000.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients’ needs. Sanofi
has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer healthcare, emerging markets and animal health.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50039969&lang=en